Inhibitory G proteins and their receptors: Emerging therapeutic targets for obesity and diabetes

Michelle E. Kimple, Joshua C. Neuman, Amelia Linnemann, Patrick J. Casey

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

The worldwide prevalence of obesity is steadily increasing, nearly doubling between 1980 and 2008. Obesity is often associated with insulin resistance, a major risk factor for type 2 diabetes mellitus (T2DM): A costly chronic disease and serious public health problem. The underlying cause of T2DM is a failure of the beta cells of the pancreas to continue to produce enough insulin to counteract insulin resistance. Most current T2DM therapeutics do not prevent continued loss of insulin secretion capacity, and those that do have the potential to preserve beta cell mass and function are not effective in all patients. Therefore, developing new methods for preventing and treating obesity and T2DM is very timely and of great significance. There is now considerable literature demonstrating a link between inhibitory guanine nucleotide-binding protein (G protein) and G protein-coupled receptor (GPCR) signaling in insulin-responsive tissues and the pathogenesis of obesity and T2DM. These studies are suggesting new and emerging therapeutic targets for these conditions. In this review, we will discuss inhibitory G proteins and GPCRs that have primary actions in the beta cell and other peripheral sites as therapeutic targets for obesity and T2DM, improving satiety, insulin resistance and/or beta cell biology.

Original languageEnglish (US)
Article numbere102
JournalExperimental and Molecular Medicine
Volume46
Issue number6
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Medical problems
GTP-Binding Proteins
Type 2 Diabetes Mellitus
Obesity
Insulin
Insulin Resistance
Therapeutics
Cytology
Guanine Nucleotides
G-Protein-Coupled Receptors
Public health
Cell Biology
Pancreas
Carrier Proteins
Chronic Disease
Public Health
Tissue

Keywords

  • Drug targets
  • G proteins
  • Insulin secretion
  • Obesity
  • Type 2 diabetes

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Molecular Medicine
  • Clinical Biochemistry
  • Medicine(all)

Cite this

Inhibitory G proteins and their receptors : Emerging therapeutic targets for obesity and diabetes. / Kimple, Michelle E.; Neuman, Joshua C.; Linnemann, Amelia; Casey, Patrick J.

In: Experimental and Molecular Medicine, Vol. 46, No. 6, e102, 01.01.2014.

Research output: Contribution to journalReview article

@article{f0ed2af818cf4590b9db5bf3817b9397,
title = "Inhibitory G proteins and their receptors: Emerging therapeutic targets for obesity and diabetes",
abstract = "The worldwide prevalence of obesity is steadily increasing, nearly doubling between 1980 and 2008. Obesity is often associated with insulin resistance, a major risk factor for type 2 diabetes mellitus (T2DM): A costly chronic disease and serious public health problem. The underlying cause of T2DM is a failure of the beta cells of the pancreas to continue to produce enough insulin to counteract insulin resistance. Most current T2DM therapeutics do not prevent continued loss of insulin secretion capacity, and those that do have the potential to preserve beta cell mass and function are not effective in all patients. Therefore, developing new methods for preventing and treating obesity and T2DM is very timely and of great significance. There is now considerable literature demonstrating a link between inhibitory guanine nucleotide-binding protein (G protein) and G protein-coupled receptor (GPCR) signaling in insulin-responsive tissues and the pathogenesis of obesity and T2DM. These studies are suggesting new and emerging therapeutic targets for these conditions. In this review, we will discuss inhibitory G proteins and GPCRs that have primary actions in the beta cell and other peripheral sites as therapeutic targets for obesity and T2DM, improving satiety, insulin resistance and/or beta cell biology.",
keywords = "Drug targets, G proteins, Insulin secretion, Obesity, Type 2 diabetes",
author = "Kimple, {Michelle E.} and Neuman, {Joshua C.} and Amelia Linnemann and Casey, {Patrick J.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1038/emm.2014.40",
language = "English (US)",
volume = "46",
journal = "Experimental and Molecular Medicine",
issn = "1226-3613",
publisher = "Korean Society of Med. Biochemistry and Mol. Biology",
number = "6",

}

TY - JOUR

T1 - Inhibitory G proteins and their receptors

T2 - Emerging therapeutic targets for obesity and diabetes

AU - Kimple, Michelle E.

AU - Neuman, Joshua C.

AU - Linnemann, Amelia

AU - Casey, Patrick J.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The worldwide prevalence of obesity is steadily increasing, nearly doubling between 1980 and 2008. Obesity is often associated with insulin resistance, a major risk factor for type 2 diabetes mellitus (T2DM): A costly chronic disease and serious public health problem. The underlying cause of T2DM is a failure of the beta cells of the pancreas to continue to produce enough insulin to counteract insulin resistance. Most current T2DM therapeutics do not prevent continued loss of insulin secretion capacity, and those that do have the potential to preserve beta cell mass and function are not effective in all patients. Therefore, developing new methods for preventing and treating obesity and T2DM is very timely and of great significance. There is now considerable literature demonstrating a link between inhibitory guanine nucleotide-binding protein (G protein) and G protein-coupled receptor (GPCR) signaling in insulin-responsive tissues and the pathogenesis of obesity and T2DM. These studies are suggesting new and emerging therapeutic targets for these conditions. In this review, we will discuss inhibitory G proteins and GPCRs that have primary actions in the beta cell and other peripheral sites as therapeutic targets for obesity and T2DM, improving satiety, insulin resistance and/or beta cell biology.

AB - The worldwide prevalence of obesity is steadily increasing, nearly doubling between 1980 and 2008. Obesity is often associated with insulin resistance, a major risk factor for type 2 diabetes mellitus (T2DM): A costly chronic disease and serious public health problem. The underlying cause of T2DM is a failure of the beta cells of the pancreas to continue to produce enough insulin to counteract insulin resistance. Most current T2DM therapeutics do not prevent continued loss of insulin secretion capacity, and those that do have the potential to preserve beta cell mass and function are not effective in all patients. Therefore, developing new methods for preventing and treating obesity and T2DM is very timely and of great significance. There is now considerable literature demonstrating a link between inhibitory guanine nucleotide-binding protein (G protein) and G protein-coupled receptor (GPCR) signaling in insulin-responsive tissues and the pathogenesis of obesity and T2DM. These studies are suggesting new and emerging therapeutic targets for these conditions. In this review, we will discuss inhibitory G proteins and GPCRs that have primary actions in the beta cell and other peripheral sites as therapeutic targets for obesity and T2DM, improving satiety, insulin resistance and/or beta cell biology.

KW - Drug targets

KW - G proteins

KW - Insulin secretion

KW - Obesity

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84903706402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903706402&partnerID=8YFLogxK

U2 - 10.1038/emm.2014.40

DO - 10.1038/emm.2014.40

M3 - Review article

C2 - 24946790

AN - SCOPUS:84903706402

VL - 46

JO - Experimental and Molecular Medicine

JF - Experimental and Molecular Medicine

SN - 1226-3613

IS - 6

M1 - e102

ER -